Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Report of the inaugural Interferon Research Summit: interferon in inflammatory diseases
Weill Cornell Med Coll, Hosp Special Surg, Mary Kirkland Ctr Lupus Res, Dept Med, New York, NY 10065 USA.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Rheumatology. Uppsala University, Science for Life Laboratory, SciLifeLab.
2018 (English)In: Lupus Science and Medicine, ISSN 2053-8790, E-ISSN 1625-9823, Vol. 5, no 1, article id e000276Article, review/survey (Refereed) Published
Abstract [en]

An international summit on interferon (IFN) in inflammatory diseases, held in Gaithersburg, Maryland, USA (4-5 May 2017), united 22 internationally renowned clinicians and scientists with backgrounds in basic science, translational science and clinical medicine. The objectives of the summit were to assess the current knowledge of the role of type I IFN in inflammatory diseases and other conditions, discuss the available clinical trial data of anti-IFN therapeutic agents and identify key clinical and therapeutic knowledge gaps and future directions to advance the treatment landscape of diseases involving the type I IFN pathway. A discussion-based consensus process was used to assess three main clinical areas: the role of type I IFN in innate immunity, the role of type I IFN in autoimmune diseases and rational therapeutic targets in the IFN pathway. These are described here, along with current knowledge gaps and resulting recommendations. The advisors unanimously agreed that, despite significant obstacles, the field should transition from an organ-based model to a pathophysiology-based model. A better understanding of the molecular pathways could help inform potential therapeutic targets, thus progressing towards personalised medicine by tailoring the therapy to each patient.

Place, publisher, year, edition, pages
2018. Vol. 5, no 1, article id e000276
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:uu:diva-398799DOI: 10.1136/lupus-2018-000276ISI: 000495994400023OAI: oai:DiVA.org:uu-398799DiVA, id: diva2:1377030
Funder
AstraZenecaAvailable from: 2019-12-10 Created: 2019-12-10 Last updated: 2019-12-10Bibliographically approved

Open Access in DiVA

fulltext(1212 kB)18 downloads
File information
File name FULLTEXT01.pdfFile size 1212 kBChecksum SHA-512
d82bbf5fefb578c12c3ef65738eb21c3c6a3c066cd1eb804d28d0d93b9b7ab0c02ca6d81af303425eff42ba5acfda95df9f499c7774aa6d11d8ea12d23e63dd4
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Rönnblom, Lars
By organisation
RheumatologyScience for Life Laboratory, SciLifeLab
In the same journal
Lupus Science and Medicine
Rheumatology and Autoimmunity

Search outside of DiVA

GoogleGoogle Scholar
Total: 18 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 27 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf